DANBURY, Conn., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) will issue its fourth quarter fiscal year 2010 financial results on December 9, 2010. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
|
December 9, 2010 schedule: |
||
|
4:00 pm EST: |
Q4 fiscal year 2010 results will be |
|
|
distributed |
||
|
4:15 pm EST: |
Conference call participants should dial: |
|
|
+1 ( 877 ) 303 - 8028 (United States) or |
||
|
+1 ( 760 ) 536 - 5167 (International) |
||
|
4:30 pm EST: |
Conference call begins |
|
Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay through the website.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel™ technology, which reformulates existing FDA-approved peptide drugs. Linjeta™ is Biodel's most advanced product candidate and has been reviewed by the FDA which issued a complete response letter. Earlier-stage product candidates include VIAtab™, a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.biodel.com.
BIOD-G
|
The Trout Group LLC |
|
|
Seth D. Lewis, +1-646-378-2952 |
|
SOURCE Biodel Inc.